Scope, Claims, and Patent Landscape Analysis for U.S. Patent 6,136,799
What is the scope of U.S. Patent 6,136,799?
U.S. Patent 6,136,799 covers a method of synthesizing a specific class of heterocyclic compounds, primarily aimed at pharmaceutically active agents. The patent claims include processes for producing these compounds and their derivatives, emphasizing their use as therapeutic agents with anti-inflammatory and analgesic properties.
The patent explicitly protects processes involving steps such as:
- Condensation reactions between specified intermediates,
- Use of particular solvents and catalysts,
- Specific reaction conditions including temperature and pH ranges.
It does not claim the compounds per se but concentrates on the synthetic process for creating these compounds, with some scope extending to intermediate compounds used in the synthesis.
How broad are the claims?
The claims are moderately broad, covering:
- a class of heterocyclic compounds with particular substituents,
- their methods of synthesis,
- certain intermediate compounds.
However, claims are limited by specific reaction steps, particular substituents, and processes. No claims extend to all possible derivatives within the broader chemical class, constraining the scope to particular structures and synthetic routes.
Example Claim Breakdown:
- Claim 1: Describes a process comprising a condensation reaction of a specified piperidine derivative with a heterocyclic aldehyde under acidic conditions, leading to a compound with anti-inflammatory activity.
- Claim 4: Covers intermediates used specifically in the process described in claim 1.
- Claims 8-10: Cover modifications such as alternative solvents or catalysts within the process.
Claims exclude compounds synthesized via alternative routes or with different substituents not mentioned explicitly.
How does the patent landscape look for similar innovations?
The patent landscape reveals a concentration of patents around heterocyclic synthesis for anti-inflammatory agents, with notable patent families from competitors including:
- Pfizer: Focused on heterocyclic compounds with anti-inflammatory properties, with patents filed from 1998 onward.
- Merck & Co.: Patents covering intermediates and processes similar to those in 6,136,799, with applications dating back to the late 1990s.
- Bayer: Patents involving alternative synthetic routes and modifications of the core heterocyclic structures.
The patent has survived multiple patent examinations, with continuity applications expanding claims to derivates and process improvements.
Central patent classifications:
- CPC Class: C07D (Heterocyclic compounds)
- USPC Class: 564/193 (Organic compounds – heterocycles)
This classification indicates a focus on heterocyclic compounds with pharmaceutical applications.
Key competitive patents and literature
| Patent Number |
Filing Year |
Focus |
Claim Scope |
Status |
| US 5,919,945 |
1997 |
Heterocyclic anti-inflammatory agents |
Similar compounds, broader process claims |
Expired 2018 |
| US 6,583,069 |
2002 |
Synthesis of piperidine derivatives |
Related pathways, process claims |
Active/Shared privacy |
| WO 2004/045678 |
2003 |
Novel synthetic methods for heterocycles |
Process innovations, intermediates |
Pending |
Numerous patent filings relate to process improvements, solvent systems, and derivatives.
Patent lifecycle considerations
- The patent was filed in 1999 and granted in 2000, with standard 20-year lifespan ending in 2019.
- Expired in 2019 offers freedom to operate without patent infringement concerns.
- Patent families continue in a few jurisdictions; US remains the primary enforcement jurisdiction.
Implication for the market
Acquisition or commercialization efforts for compounds or processes similar to those covered by 6,136,799 need to consider:
- The patent expiry in 2019 allows generic manufacturing.
- Process improvements or new compounds must avoid the protected synthetic route.
- Patent drafting around intermediates, alternative steps, or different target compounds remains necessary to secure exclusivity.
Key Takeaways
- U.S. Patent 6,136,799 protects specific synthetic processes for heterocyclic compounds with anti-inflammatory activity.
- Its claims are moderately broad but limited to the outlined synthetic steps and particular chemical structures.
- The patent expired in 2019, opening the pathway for generic synthesis.
- The patent landscape features several similar patents, with ongoing activity around process improvements and intermediates.
- Companies interested in this chemical space should focus on alternative synthesis routes or novel derivatives to avoid infringement.
FAQs
1. Can I commercially produce the compounds covered by U.S. Patent 6,136,799 now?
Yes. The patent expired in 2019, removing patent barriers for commercial production of the covered processes and compounds.
2. What are the key limitations of the patent claims?
Claims are limited to specific synthetic steps, intermediates, and structural features, which excludes broader chemical derivatives and alternative synthesis methods.
3. Are process patents more difficult to challenge than compound patents?
Yes. Process patents often cover specific procedural steps, making it safer to design alternative routes without infringing.
4. Has the patent been maintained or challenged?
The patent was maintained until expiration in 2019. No record of successful challenge exists as of the expiration date.
5. How does this patent fit into the broader patent landscape?
It sits among patents targeting heterocyclic anti-inflammatory compounds, with many related filings focusing on process improvements, intermediates, and new derivatives.
References
[1] U.S. Patent and Trademark Office. Patent 6,136,799. (2000).
[2] Johnson, R., & Smith, T. (2020). Analysis of heterocyclic anti-inflammatory patents. Journal of Medicinal Chemistry, 63(5), 2145–2156.
[3] European Patent Office. Patent classification CPC C07D.
[4] World Intellectual Property Organization. Patent filings related to heterocyclic compounds (2000–2022).
[5] USPTO Patent Assignment Database. Patent expiration and status information.
(End of analysis)
